8-K: vTv Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

vTv Therapeutics reports Q1 2025 financial results and provides an update on the Phase 3 trial of cadisegliatin for type 1 diabetes, with topline data expected in the second half of 2026.

Summary

• vTv Therapeutics announced its first quarter 2025 financial results and provided a corporate update on May 15, 2025.
• The company is focused on developing cadisegliatin as an oral adjunctive therapy for type 1 diabetes (T1D).
• Screening has been reinitiated in the Phase 3 CATT1 trial evaluating cadisegliatin.
• A protocol amendment was submitted to reduce the CATT1 trial duration from 12 to 6 months, expediting the timeline for topline data.
• Topline Phase 3 data for cadisegliatin is expected in the second half of 2026.
• The company's cash position as of March 31, 2025, was $31.1 million, compared to $36.7 million as of December 31, 2024.
• R&D expenses were $2.8 million for the three months ended March 31, 2025, compared to $2.6 million for the same period in 2024.
• G&A expenses were $3.7 million for the three months ended March 31, 2025, compared to $4.0 million for the same period in 2024.
• Net loss attributable to vTv shareholders for the three months ended March 31, 2025, was $5.1 million, or $0.77 per basic share, compared to a net loss of $4.9 million, or $1.17 per basic share, for the same period a year ago.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is progressing with its clinical trial, but it is still incurring losses and has a decreasing cash position. The shortened trial duration is a positive development.

Positives

• Screening reinitiated for the Cadisegliatin Phase 3 Trial.
• Protocol Amendment for CATT1 Phase 3 Trial to reduce the overall duration of the trial from 12 to 6 months.
• The company's cash position as of March 31, 2025, was $31.1 million.
• G&A expenses decreased to $3.7 million for the three months ended March 31, 2025, compared to $4.0 million for the same period in 2024.

Negatives

• The company experienced a net loss attributable to vTv shareholders of $5.1 million for the three months ended March 31, 2025.
• The company's cash position decreased from $36.7 million as of December 31, 2024, to $31.1 million as of March 31, 2025.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The success of cadisegliatin is not guaranteed, and it may not receive health authority approval or become commercially available.
• The company's future financial position and revenue are subject to various risks and uncertainties.

Future Outlook

Topline Phase 3 data for cadisegliatin is expected in the second half of 2026.

Management Comments

• Our late stage cadisegliatin program is advancing with potential to be the first oral adjunct therapy for T1D, said Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics.
• We reinitiated screening in our Phase 3 CATT1 study and, based upon the recent protocol amendment to shorten the study from 12 to 6 months, we expect topline Phase 3 data for cadisegliatin in the second half of 2026.

Industry Context

vTv Therapeutics is focused on developing cadisegliatin as a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes, which could provide a significant advancement in the treatment of this chronic disease.

Comparison to Industry Standards

• It's difficult to compare vTv Therapeutics directly to industry standards without knowing the specific stage and focus of comparable companies.
• However, companies like Lexicon Pharmaceuticals, which developed Sotagliflozin (Zynquista) for type 1 diabetes, provide a benchmark for the challenges and potential rewards of developing adjunctive therapies for diabetes.
• The success of Zynquista, despite its eventual withdrawal from the market, highlights the demand for novel treatments in this space.
• vTv's focus on an oral glucokinase activator differentiates it from other approaches, but also introduces unique regulatory and clinical risks.

Stakeholder Impact

• Shareholders are impacted by the financial performance and the progress of the clinical trial.
• Patients with type 1 diabetes could benefit from a successful development of cadisegliatin.
• Employees are impacted by the company's financial stability and future prospects.

Next Steps

• Continue screening in the CATT1 Phase 3 trial.
• Await topline Phase 3 data for cadisegliatin in the second half of 2026.

Key Dates

Keywords

cadisegliatin, type 1 diabetes, T1D, Phase 3 trial, financial results, vTv Therapeutics, CATT1, glucokinase activator